Trend Chart on Innovative BioIndustries is a FREE NEWSLETTER published by BioPharmAnalyses and OctopusyX BioConsulting.
Do not hesitate to share it with colleagues and anybody who may be interested in these topics.
Contents of the last issue.
-GSK and CureVac announce strategic mRNA technology collaboration.
-Gene therapy development in hearing research in China.
-Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike.
-Moderna announces interim results from Phase 1 Study of its mRNA vaccine against COVID-19.
-Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2.
-Biogen plans to initiate phase 4 study evaluating benefit of Spinraza® in patients treated with Zolgensma®.
-Forge Biologics launches with 40 MUS$ series A financing to manufacture and develop gene therapies.
-Translate Bio announces closing of expanded collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for all infectious diseases.
-Encoded Therapeutics announces 135MUS$ Series D financing to support first clinical trials in Dravet syndrome.
-New Tufts CSDD white paper highlights changes to the drug development workforce in response to digital disruption and transformation.
Feature Story
GSK and CureVac announced on July 20th the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform. mRNA (messenger RNA) technology is a rapidly progressing, cutting-edge platform for the development of new vaccines and medicines, potentially expanding the range of diseases which can be prevented or treated, while also promising to significantly speed up development and manufacturing. mRNA enables protein synthesis in the human body, carrying the genetic code required for cells to manufacture and express proteins. By using mRNA technology in vaccines and medicines, specific proteins, or antigens, can be produced by the body’s own cells, enabling the human immune system to prevent or fight disease. CureVac’s leadership in mRNA technology, along with its mRNA manufacturing capability, complements GSKs existing scientific leadership in vaccines, including GSKs own self-amplifying mRNA (SAM) vaccine technology platform, and further builds on GSKs growing capability in mAbs innovation, aligned to its R&D focus on the science of immunology. Advancing mRNA-based vaccine and treatment technologies is also expected to play a role in further improving response against future pandemics.
For further information, see CureVac.
Related Informations / Publications.
-JUL 2020: EIB and European Commission provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing.
Results / Comments: The transaction is financed under the Infectious Diseases Finance Facility of Horizon 2020, the EU research and innovation programme for 2014-2020.
Link: Press Release
-JUN 2020: CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate
Link: Press Release
-JUN 2020: German Federal Government invests 300 Million Euros in CureVac
Link: Press Release
For the full issue see BioPharmAnalyses (http://biopharmanalyses.fr/trend-chart-on-innovative-bioindustries-july-2020-29th/)
Last Report
Four Unicorns in the Race for a mRNA-based Vaccine against Covid-19, BioNTech, Curevac, Moderna, Translate Bio….
These four biotech are now developing mRNA-based vaccine
candidates against SARS-CoV-2 and have reached the clinical stage. These
programs could lead to short-term boosts for these companies’s shares. However,
addressing epidemics is still a risky business. So far, it isn’t the most
profitable area for companies and decision makers in health, industry and
politics need a comprehensive overview of their businesses. Our latest report “Four Unicorns in the
Race for a mRNA-based Vaccine against Covid-19” can help you to find out main assets and strengths of these
companies…This 56-page publication lists and develops in detail for each
company:
• General informations
(location, website, FTE, management….)
• Core Business and Corporate informations
• Recent Fundings and Financial Highlights (grants, funding rounds,
revenues, R&D expenses….)
• Pipeline (target indications mechanism of action, stage of
development…)
• Orphan drug designations
• Ongoing Clinical Trials (phase, status, start and completion date, planned enrollment…)
• Latest Developments
• Latest Scientific Publications
Want to have a look at this report ? Click to download sample pages